Physician profile
Travis L Vickers
NPI 1295095511
$3,156.64
in general payments reported to CMS, 2019-2025
25 companies · $764 in 2025
The $764 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $33.90 · 2021: $60.78 · 2022: $140 · 2023: $294 · 2024: $868 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.92 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,102.02 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Gilead Sciences, INC. | $305.81 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.84 | 2019-2025 | Eohilia, Entyvio |
| Janssen Biotech, INC. | $206.04 | 2023-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $144.55 | 2019-2025 | |
| Qol Medical, LLC | $129.39 | 2019-2024 | Sucraid |
| Thd America, INC. | $123.76 | 2019 | |
| Aimmune Therapeutics, INC. | $120.38 | 2024-2025 | Zenpep, Vowst |
| Cook Medical LLC | $119.79 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.45 | 2024-2025 | Xifaxan |
| Boston Scientific Corporation | $93.58 | 2019-2025 | General - Pain Management |
| Pfizer INC. | $82.78 | 2019-2025 | |
| Ucb, INC. | $76.77 | 2019 | |
| Phathom Pharmaceuticals, INC. | $46.87 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $41.56 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $38.39 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $30.99 | 2024-2025 | Sutab, Suflave |
| Medtronic, INC. | $30.99 | 2024 | Gi Genius |
| Olympus America INC. | $28.81 | 2019 | |
| Merck Sharp & Dohme LLC | $25.16 | 2024 | Dificid |
| Celltrion USA INC. | $23.54 | 2025 | Vegzelma |
| Genzyme Corporation | $22.69 | 2025 | |
| Shire North American Group INC | $19.22 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.04 | 2025 | Dupixent |
| Biocon Biologics INC | $17.22 | 2025 | Yesintek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Vickers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.